Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BZB8
UPID:
CPEB1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BZB8; B7Z6C6; Q86W46; Q8IV41; Q9BZB7; Q9H8V5
Background:
Cytoplasmic polyadenylation element-binding protein 1 (CPEB1) plays a pivotal role in mRNA cytoplasmic polyadenylation and translation initiation, crucial for oocyte maturation, early development, and synaptic functions in neurons. It binds to the cytoplasmic polyadenylation element within the mRNA 3'-UTR, undergoing a significant conformational change upon RNA binding. CPEB1's involvement extends to mRNA transport to dendrites, stress granule assembly, and cell cycle progression, specifically prophase entry.
Therapeutic significance:
Understanding the role of Cytoplasmic polyadenylation element-binding protein 1 could open doors to potential therapeutic strategies.